Brief: Genmab Says Data Analyses Show Epcoritamab Induces Durable, Complete Responses in Patients With DLBCL

Genmab A/S

10/12/2024 07:54

Dec 10 (Reuters) - Genmab A/S  GMAB.CO :
    * SAID ON MONDAY TWO DATA ANALYSES FROM CLINICAL TRIALS SHOW EPCORITAMAB (DUOBODY CD3XCD20)
INDUCES DURABLE, COMPLETE RESPONSES AS MONOTHERAPY AND COMBINATION TREATMENT IN PATIENTS WITH
DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    * RESULTS FROM ARM 1 OF THE EPCORE NHL-2 TRIAL SHOW TREATMENT WITH EPCORITAMAB COMBINATION
LED TO
AN OVERALL RESPONSE RATE (ORR) OF 100 PERCENT AND A COMPLETE RESPONSE (CR) RATE OF 87 PERCENT IN
HIGH-RISK PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    * EXTENDED FOLLOW-UP DATA FROM EPCORE NHL-1 TRIAL DEMONSTRATES DURABILITY OF RESPONSES AND
LONG-TERM SAFETY OF EPCORITAMAB MONOTHERAPY FOR PATIENTS WITH CHALLENGING-TO-TREAT
RELAPSED/REFRACTORY (R/R) DLBCL
    * 

Source text: Link
Further company coverage:  GMAB.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))